Angiogenic factors in preeclampsia: so complex, so simple?

Hoechst.htm 23. Cointe D, Beliard R, Jorieux S et al. Unusual N-glycosylation of a recombinant human erythropoietin expressed in a human lymphoblastoid cell line does not alter its biological properties. Glycobiology 2000; 10: 511–519 24. Shahrokh Z, Flatman S, Davies M, Baycroft A, Heartlein M. Erythropoietin produced by a human cell line has only trace levels of potentially immunogenic N-glycolylneuraminic acid residues. Haematologica 2006; 91 [S1]: 208 (Abstract) 25. Noguchi A, Mukuria CJ, Suzuki E et al. Immunogenicity of N-glycolylneuraminic acid-containing carbohydrate chains of recombinant human erythropoietin expressed in Chinese hamster ovary cells. J Biochem (Tokyo) 1995; 117: 59–62 26. Tangvoranuntakul P, Gagneux P, Diaz S et al. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci USA 2003; 100: 12045–12050 27. Nguyen DH, Tangvoranuntakul P, Varki A. Effects of natural human antibodies against a nonhuman sialic acid that metabolically incorporates into activated and malignant immune cells. J Immunol 2005; 175: 228–236 28. Kwan JT, Pratt RD. Epoetin-d, erythropoietin produced in a human cell line, in the management of anaemia in predialysis chronic kidney disease patients. Curr Med Res Opin 2007; 23: 307–311 29. Spinowitz BS, Pratt RD. Epoetin-d is effective for the management of anaemia associated with chronic kidney disease. Curr Med Res Opin 2006; 22: 2507–2513 30. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001; 84: 3–10 31. Elliott S, Lorenzini T, Asher S et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 2003; 21: 414–421 32. Jelkmann W. The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur J Haematol 2002; 69: 265–274 33. MacDougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol 2000; 20: 375–381 34. Wish JB. The economic realities of erythropoiesis-stimulating agent therapy in kidney disease. Kidney Int 2006; 70: S21–S25 35. MacDougall IC. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 2005; 4: 436–440 36. SteadRB, Lambert J,WesselsD et al.Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 2006; 108: 1830–1834 37. Kochendoerfer GG. Site-specific polymer modification of therapeutic proteins. Curr Opin Chem Biol 2005; 9: 555–560